AMRN Logo

Amarin Corporation plc (AMRN) 

NASDAQ
Market Cap
$189.18M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
285 of 960
Rank in Industry
173 of 550

Largest Insider Buys in Sector

AMRN Stock Price History Chart

AMRN Stock Performance

About Amarin Corporation plc

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with …

Insider Activity of Amarin Corporation plc

Over the last 12 months, insiders at Amarin Corporation plc have bought $118,124 and sold $0 worth of Amarin Corporation plc stock.

On average, over the past 5 years, insiders at Amarin Corporation plc have bought $174,734 and sold $9.75M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Berg Aaron (President and CEO) — $102,400. Holt Patrick (President and CEO) — $15,724.

The last purchase of 160,000 shares for transaction amount of $102,400 was made by Berg Aaron (President and CEO) on 2024‑08‑02.

List of Insider Buy and Sell Transactions, Amarin Corporation plc

2024-08-02PurchasePresident and CEO
160,000
0.0389%
$0.64$102,400-7.81%
2024-01-22PurchasePresident and CEO
14,426
0.0033%
$1.09$15,724-31.37%
2023-12-12SaleChief Scientific Officer
34,131
0.0084%
$0.79$26,963+7.55%
2023-08-16PurchasePresident and CEO
300,000
0.0723%
$1.04$312,315-17.88%
2022-06-13Purchase
55,000
0.0137%
$1.69$92,730-21.76%
2021-12-15Purchasedirector
2,000
0.0005%
$3.15$6,310-52.31%
2021-12-14Purchasedirector
10,000
0.0025%
$3.27$32,689-52.00%
2021-08-12SaleSVP and CFO
120,000
0.0282%
$5.25$630,240-41.05%
2021-06-04Purchasedirector
10,000
0.0026%
$4.54$45,350-17.42%
2021-06-03Purchasedirector
5,000
0.0013%
$4.62$23,115-19.61%
2021-02-01SaleChief Scientific Officer
435,456
0.11%
$8.06$3.51M-39.85%
2021-01-27SaleChief Scientific Officer
843,258
0.2332%
$8.01$6.76M-33.52%
2020-11-30Purchasedirector
50,000
0.0125%
$4.86$243,035+1.61%
2020-11-11SalePresident and CEO
827,130
0.2094%
$4.07$3.36M+22.63%
2020-11-10SalePresident and CEO
307,680
0.0792%
$4.13$1.27M+22.63%
2020-03-04SalePresident and CEO
400,000
0.1106%
$15.99$6.4M-58.77%
2020-01-03Saledirector
600,000
0.0965%
$12.17$7.3M-67.88%
2019-12-16SaleCHIEF COMMERCIAL OFFICER
86,506
0.02%
$19.03$1.65M-70.15%
2019-12-16Saledirector
200,000
0.0424%
$17.42$3.48M-70.15%
2019-12-16SaleSVP and CFO
50,000
0.0142%
$23.36$1.17M-70.15%

Insider Historical Profitability

20.36%
Berg AaronPresident and CEO
805380
0.1958%
$0.4614
Holt PatrickPresident and CEO
314426
0.0765%
$0.4620
THERO JOHN FPresident and CEO
2739000
0.666%
$0.4669+54.85%
Zakrzewski Joseph Sdirector
196547
0.0478%
$0.46316<0.0001%
WOLD OLSEN PER
149000
0.0362%
$0.4610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Sarissa Capital Management LP$22.14M6.0524.85M0%+$03.87
Kynam Capital Management Lp$10.71M2.9312.02M0%+$00.14
DG Capital$5.74M1.576.44M+19.23%+$925,812.883.72
Eversept Partners LP$5.53M1.516.21M+1.92%+$104,440.070.43
Morgan Stanley$3.22M0.883.61M-35.1%-$1.74M<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.